About MEDIFAST INC Common Stock Company overview from Wikipedia

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

Subsidiaries

The company owns five subsidiaries:

Jason Pharmaceuticals, Inc.

Take Shape for Life, Inc. (TSFL) (renamed Optavia from July 2017)

Jason Enterprises, Inc.

Jason Properties, LLC

Seven Crondall, LLC

History

William Vitale, a medical doctor, founded Medifast in 1980. He sold his products directly to other doctors, who in turn prescribed them to their patients alongside behavioural counselling techniques.

The company is publicly traded on the New York Stock Exchange (symbol: MED).

On July 17, 1995, HealthRite (predecessor of Medifast) changed its name from Vitamin Specialties Corp.

In 2000 the company pivoted to a direct-to-consumer marketing program with the help of Jason Pharmaceuticals and in 2001, the company changed its name to Medifast, Inc. In 2002, Retired Marine Colonel Bradley T. MacDonald, Chairman of the Board at the time, along with clinical specialist Dr. Wayne Scott Andersen, created Take Shape For Life as a personal Coach to the Client system and the company's “Habits of Health System.”

In October 2010, Medifast was ranked number 1 on Forbes magazine's list of "America's 100 Best Small Companies". The company was ranked 18th on the 2014 list.

Medifast was named one of Forbes's 100 Most Trustworthy Companies in America in 2016 and 2017.

In July 2017, Medifast changed the name of its subsidiary Take Shape For Life to Optavia and introduced a new line of products, Optavia Essentials, directly sold from Coaches to clients.

In October 2017, Medifast relocated its headquarters to Baltimore from Owings Mills, Maryland. The company is public with a market capitalization of $2.106 billion, as of June 2022.

In December 2023, Medifast announced a partnership with LifeMD, a provider of virtual healthcare services. Under the agreement, Medifast will use LifeMD's virtual platform to offer Medifast clients a clinically supported weight management program, including the option for prescription GLP-1 medications where clinically appropriate. In return, LifeMD will provide its patients with an independent Medifast Coach and additional lifestyle support services for weight management.

False advertising settlement

In September 2012, Medifast's subsidiary, Jason Pharmaceuticals, paid a $3.7 million USD civil penalty for false advertising. The Federal Trade Commission and United States Department of Justice said that advertisements for the "Medifast 5 & 1 Plan" low-calorie diet told consumers they could "lose up to 2-5 pounds per week", and that these weight-loss claims lacked a reasonable scientific basis, and were unsubstantiated. Under the settlement, any future claims made by the company must be backed by at least one human clinical study.

Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗

Wikidata ↗

MED Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

Price

$11.31

Market Cap

$124M

P/E (TTM)

-6.7

EPS (TTM)

$-1.70

Revenue (TTM)

$386M

Div Yield

0.16%

ROE

-9.0%

Debt/Equity

—

52W Range

$9 – $15

MED Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

10-Year Performance Revenue, net income, margins and EPS trends

Revenue & Net Income $386M

2016-12-31 → 2025-12-31

EPS $-1.70

2016-12-31 → 2025-12-31

Free Cash Flow $1M

2016-12-31 → 2025-12-31

Margins -4.8%

2016-12-31 → 2025-12-31

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric

5Y trend

MED

Peer Median

P/E (TTM)

-6.7

14.8

P/S (TTM)

0.3

0.7

P/B

0.6

2.9

Price / FCF

99.5

—

Profitability Gross, operating and net margins; ROE, ROA, ROIC

Metric

5Y trend

MED

Peer Median

Gross Margin

71.3%

69.3%

Operating Margin

-3.7%

—

Net Profit Margin

-4.8%

4.4%

ROA

-7.0%

6.3%

ROE

-9.0%

14.0%

ROIC

-23.7%

—

Financial Health Debt, liquidity, solvency — balance sheet strength

Metric

5Y trend

MED

Peer Median

Current Ratio

4.7

2.4

Quick Ratio

3.9

—

Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR

Metric

5Y trend

MED

Peer Median

Revenue YoY

-36.0%

—

Revenue CAGR 3Y

-37.7%

—

Revenue CAGR 5Y

-16.2%

—

EPS YoY

-97.9%

—

Net Income YoY

-97.9%

—

Per Share Metrics EPS, book value per share, cash flow per share, dividend per share

Metric

5Y trend

MED

Peer Median

EPS (Diluted)

$-1.70

—

Capital Efficiency Asset turnover, inventory turnover, receivables turnover

Metric

5Y trend

MED

Peer Median

Payout Ratio

-1.0%

—

Dividends Yield, payout ratio, dividend history, 5Y CAGR

Dividend Yield

0.16%

Payout Ratio

-1.0%

5Y Div CAGR

—

Ex-date	Amount
Sept. 18, 2023	$1.6500
June 26, 2023	$1.6500
March 27, 2023	$1.6500
Dec. 19, 2022	$1.6400
Sept. 19, 2022	$1.6400
June 27, 2022	$1.6400
March 28, 2022	$1.6400
Dec. 20, 2021	$1.4200
Sept. 20, 2021	$1.4200
June 21, 2021	$1.4200
March 29, 2021	$1.4200
Dec. 21, 2020	$1.1300
Sept. 21, 2020	$1.1300
June 29, 2020	$1.1300
March 30, 2020	$1.1300
Dec. 26, 2019	$1.1300
Sept. 26, 2019	$0.7500
June 27, 2019	$0.7500
March 28, 2019	$0.7500
Dec. 20, 2018	$0.7500

MED Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

SELL 9 analysts

Strong Buy 0 0.0%
Buy 0 0.0%
Hold 4 44.4%
Sell 4 44.4%
Strong Sell 1 11.1%

12-Month Price Target

1 analysts · 2026-08-16

Low $12.00

High $12.00

Median target $12.00 +6.1%

Mean target $12.00 +6.1%

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

Avg Surprise

0.11%

Period	EPS Actual	EPS Est	Surprise
June 30, 2026	$-0.28	$-0.66	0.38%
March 31, 2026	$-0.19	$-0.53	0.34%
Dec. 31, 2025	$-1.65	$-0.83	-0.82%
Sept. 30, 2025	$-0.21	$-0.39	0.18%
June 30, 2025	$0.22	$-0.22	0.44%
March 31, 2025	$-0.11	$-0.27	0.16%

Peer comparison (GICS sub-industry) Key metrics vs sector peers

Ticker	Market Cap	P/E	Rev YoY	Net Margin	ROE	Gross Margin
MED	$117M	-6.3	-36.0%	-4.8%	-9.0%	71.3%
NATR	$378M	20.4	5.7%	4.1%	12.0%	72.4%
USNA	$355M	33.5	8.3%	1.2%	2.0%	78.3%
NAGE	$507M	31.8	29.9%	13.4%	24.7%	64.3%
NUS	—	3.0	-14.3%	10.8%	22.0%	69.5%
FTLF	—	25.8	26.4%	—	—	—
SKIN	$177M	-8.7	-10.0%	-3.2%	-14.1%	65.3%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

Income Statement 15

Annual Income Statement data for MED
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	$386M	$602M	$1.07B	$1.60B	$1.53B	$935M	$714M	$501M	$302M	$275M	$273M	$285M
Cost of Revenue	$111M	$158M	$296M	$458M	$398M	$237M	$177M	$121M	$74M	$69M	$71M	$76M
Gross Profit	$275M	$445M	$776M	$1.14B	$1.13B	$698M	$537M	$380M	$228M	$206M	$201M	$209M
R&D Expense	$4M	$5M	$5M	$4M	$4M	$3M	$3M	$2M	$2M	$2M	$2M	$1M
SG&A Expense	$289M	$442M	$649M	$956M	$911M	$564M	$446M	$311M	$188M	$179M	$173M	$179M
Operating Income	$-14M	$3M	$126M	$185M	$216M	$134M	$91M	$69M	$40M	$27M	$29M	$30M
Other Non-op	$3M	$-4M	$-95.0K	$-747.0K	$119.0K	$-140.0K	$29.0K	$179.0K	$136.0K	$-20.0K	$326.0K	$731.0K
Pretax Income	$-6M	$4M	$129M	$184M	$216M	$134M	$92M	$71M	$40M	$27M	$30M	$32M
Income Tax	$13M	$2M	$29M	$40M	$52M	$31M	$14M	$15M	$13M	$9M	$10M	$11M
Net Income	$-19M	$2M	$99M	$144M	$164M	$103M	$78M	$56M	$28M	$18M	$20M	$13M
EPS (Basic)	$-1.70	$0.19	$9.13	$12.82	$14.01	$8.74	$6.62	$4.67	$2.32	$1.51	$1.68	$1.04
EPS (Diluted)	$-1.70	$0.19	$9.10	$12.73	$13.89	$8.68	$6.43	$4.62	$2.29	$1.49	$1.66	$1.03
Shares (Basic)	10,981,000	10,930,000	10,884,000	11,195,000	11,705,000	11,771,000	11,771,000	11,947,000	11,924,000	11,842,000	11,959,000	12,670,000
Shares (Diluted)	10,981,000	10,963,000	10,921,000	11,276,000	11,813,000	11,850,000	12,117,000	12,079,000	12,088,000	11,947,000	12,071,000	12,778,000
EBITDA	$29.0K	$16M	$140M	$196M	$223M	$141M	$96M	$73M	$44M	$32M	$36M	·

Balance Sheet 24

Annual Balance Sheet data for MED
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Cash & Equivalents	$89M	$91M	$94M	$88M	$104M	$164M	$77M	$81M	$75M	$52M	$42M	$24M
Short-term Investments	$78M	$71M	$56M	$0	$5M	$11M	$16M	$20M	$24M	$24M	$25M	$28M
Receivables	·	·	·	·	·	$584.0K	$1M	$1M	$576.0K	$1M	$2M	$2M
Inventory	$20M	$42M	$55M	$119M	$180M	$53M	$49M	$39M	$19M	$18M	$13M	$16M
Prepaid Expense	$9M	$10M	$11M	$16M	$16M	$6M	$6M	$5M	$4M	$4M	$3M	$3M
Current Assets	$202M	$214M	$224M	$223M	$307M	$234M	$154M	$146M	$125M	$101M	$87M	$82M
PP&E (Net)	$31M	$38M	$51M	$57M	$56M	$28M	$26M	$20M	$19M	$20M	$29M	$33M
PP&E (Gross)	$99M	$96M	$99M	$97M	$89M	$55M	$49M	$54M	$52M	$56M	$75M	$74M
Accum. Depreciation	$68M	$58M	$47M	$40M	$33M	$27M	$23M	$35M	$33M	$36M	$46M	$40M
Other Non-current Assets	$8M	$10M	$15M	$12M	$6M	$3M	$353.0K	$1M	$2M	$162.0K	$205.0K	$497.0K
Total Assets	$248M	$284M	$310M	$316M	$398M	$276M	$195M	$169M	$146M	$121M	$116M	$116M
Accounts Payable	$38M	$56M	$86M	$135M	$163M	$108M	$76M	$60M	$37M	$24M	$23M	$22M
Current Liabilities	$43M	$64M	$92M	$141M	$170M	$111M	$79M	$60M	$37M	$24M	$24M	$27M
Capital Leases	$6M	$10M	$16M	$20M	$26M	$7M	$10M	·	·	·	$0	$242.0K
Deferred Tax	·	·	·	·	·	·	·	·	$208.0K	$779.0K	$4M	$5M
Total Liabilities	$49M	$74M	$108M	$161M	$196M	$119M	$90M	$60M	$37M	$25M	$28M	$35M
Common Stock	$11.0K	$11.0K	$11.0K	$11.0K	$12.0K	$12.0K	$12.0K	$12.0K	$12.0K	$12.0K	$12.0K	$12.0K
Paid-in Capital	$40M	$33M	$27M	$22M	$12M	$8M	·	$9M	$5M	$3M	$0	$1M
Retained Earnings	$158M	$177M	$175M	$140M	$190M	$154M	$169M	$131M	$104M	$93M	$89M	$79M
Treasury Stock	·	·	$0	$6M	$0	$5M	$64M	$31M	·	·	·	$0
AOCI	$234.0K	$180.0K	$248.0K	$24.0K	$111.0K	$41.0K	$25.0K	$-173.0K	$-160.0K	$-165.0K	$-62.0K	$435.0K
Stockholders' Equity	$199M	$210M	$201M	$155M	$202M	$157M	$105M	$109M	$107M	$96M	$89M	$80M
Liabilities + Equity	$248M	$284M	$310M	$316M	$398M	$276M	$195M	$169M	$146M	$121M	$116M	$116M
Shares Outstanding	10,991,000	10,938,000	10,896,000	10,873,000	11,593,000	11,772,000	11,764,000	11,868,000	11,971,000	11,871,000	11,797,000	12,075,764

Cash Flow 16

Annual Cash Flow data for MED
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
D&A	$14M	$13M	$13M	$11M	$7M	$4M	$5M	$4M	$4M	$5M	$7M	$8M
Stock-based Comp	$8M	$7M	$8M	$11M	$10M	$7M	$5M	$3M	$4M	$3M	$3M	$4M
Deferred Tax	$11M	$-7M	$1M	$-924.0K	$-4M	$601.0K	$2M	$-3M	$-623.0K	$-3M	$-106.0K	$286.0K
Restructuring	·	·	·	·	·	·	·	·	·	$1M	·	·
Other Non-cash	$-8M	$10M	$26M	$30M	$-82M	$28M	$-4M	$155.0K	$8M	$2M	$-737.0K	·
Operating Cash Flow	$7M	$24M	$148M	$195M	$95M	$145M	$84M	$61M	$43M	$25M	$29M	$26M
CapEx	$6M	$7M	$6M	$17M	$34M	$6M	$10M	$5M	$3M	$3M	$3M	$7M
Investing Cash Flow	$-8M	$-27M	$-61M	$-11M	$-29M	$-1M	$-6M	$-1M	$-3M	$-2M	$-189.0K	$-3M
Net Debt Issued	·	·	·	·	·	·	·	·	·	$-219.0K	$-255.0K	·
Stock Repurchased	$0	$0	$4M	$126M	$56M	$5M	$33M	$30M	·	·	$11M	$34M
Net Stock Activity	$0	$0	$-4M	$-126M	$-56M	$-5M	$-33M	$-30M	·	·	$-11M	·
Dividends Paid	$195.0K	$715.0K	$73M	$72M	$64M	$53M	$35M	$23M	$15M	$12M	·	·
Financing Cash Flow	$-564.0K	$-2M	$-80M	$-200M	$-125M	$-57M	$-82M	$-53M	$-17M	$-13M	$-12M	$-35M
Net Change in Cash	$-2M	$-4M	$7M	$-16M	$-60M	$87M	$-4M	$6M	$23M	$10M	$18M	$-12M
Taxes Paid	$10M	$-2M	$34M	$37M	·	·	·	·	·	·	·	·
Free Cash Flow	$1M	$17M	$141M	$178M	$60M	$139M	$74M	$56M	$40M	$22M	$27M	·

Profitability 8

Annual Profitability data for MED
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Gross Margin	71.3%	73.8%	72.4%	71.3%	73.9%	74.7%	75.2%	75.8%	75.5%	74.9%	73.8%	·
Operating Margin	-3.7%	0.48%	11.8%	11.6%	14.2%	14.3%	12.8%	13.8%	13.1%	9.8%	10.5%	·
Net Margin	-4.8%	0.35%	9.3%	9.0%	10.8%	11.0%	10.9%	11.1%	9.2%	6.5%	7.3%	·
Pretax Margin	-1.5%	0.63%	12.0%	11.5%	14.2%	14.4%	12.9%	14.1%	13.4%	9.9%	10.9%	·
EBITDA Margin	0.01%	2.6%	13.0%	12.2%	14.6%	15.1%	13.4%	14.7%	14.5%	11.8%	13.1%	·
ROA	-7.0%	0.70%	31.8%	40.2%	48.6%	43.7%	42.8%	35.4%	20.8%	15.0%	17.2%	·
ROE	-9.0%	1.0%	50.4%	94.0%	82.3%	69.2%	72.1%	50.5%	27.1%	19.3%	23.7%	·
ROIC	-23.7%	0.76%	48.4%	93.0%	81.1%	65.4%	73.3%	50.1%	25.1%	18.4%	21.3%	·

Liquidity & Solvency 2

Annual Liquidity & Solvency data for MED
Metric	Trend	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Current Ratio		4.7	3.3	2.4	1.6	1.8	2.1	1.9	2.4	3.4	4.1	3.7	·
Quick Ratio		3.9	2.5	1.0	0.6	0.6	1.6	1.2	1.7	2.7	3.2	2.9	·

Efficiency 3

Annual Efficiency data for MED
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Asset Turnover	1.4	2.0	3.4	4.5	4.5	4.0	3.9	3.2	2.3	2.3	2.3	·
Inventory Turnover	3.5	3.3	3.4	3.1	3.4	4.6	4.0	4.1	3.9	4.4	4.9	·
Receivables Turnover	·	·	·	·	·	925.1	583.1	467.4	307.2	181.8	166.2	·

Per Share 6

Annual Per Share data for MED
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Book Value / Share	$18.10	$19.21	$18.49	$14.26	$17.47	$13.36	$8.91	$9.19	$9.07	$8.09	$7.51	·
Revenue / Share	$35.13	$54.95	$98.16	$141.77	$129.19	$78.89	$58.90	$41.48	$24.95	$22.98	$22.60	·
Cash Flow / Share	$0.62	$2.23	$13.52	$17.26	$8.00	$12.25	$6.95	$5.03	$3.58	$2.12	$2.44	·
Cash / Share	$8.13	$8.31	$8.67	$8.06	$8.99	$13.91	$6.54	$6.86	$6.27	$4.42	$3.56	·
Dividend / Share	$0	$0	$5	$7	$6	$5	$3	$2	$1	$1	$0	$0
EPS (TTM)	$-1.70	$0.19	$9.10	$12.73	$13.89	$8.68	$6.43	$4.62	$2.29	$1.49	$1.66	$1.03

Growth Rates 8

Annual Growth Rates data for MED
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue YoY	-36.0%	-43.8%	-32.9%	4.8%	63.2%	·	·	·	·	·	·	·
Revenue CAGR 3Y	-37.7%	-26.6%	4.7%	·	·	·	·	·	·	·	·	·
Revenue CAGR 5Y	-16.2%	·	·	·	·	·	·	·	·	·	·	·
EPS YoY	·	-97.9%	-28.5%	-8.3%	60.0%	·	·	·	·	·	·	·
EPS CAGR 3Y	·	-76.1%	1.6%	·	·	·	·	·	·	·	·	·
Net Income YoY	·	-97.9%	-30.8%	-12.5%	59.5%	·	·	·	·	·	·	·
Net Income CAGR 3Y	·	-76.6%	-1.1%	·	·	·	·	·	·	·	·	·
Dividend CAGR 5Y	-67.4%	·	·	·	·	·	·	·	·	·	·	·

Valuation (TTM) 13

Annual Valuation (TTM) data for MED
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue TTM	$386M	$602M	$1.07B	$1.60B	$1.53B	$935M	$714M	$501M	$302M	$275M	$273M	$285M
Net Income TTM	$-19M	$2M	$99M	$144M	$164M	$103M	$78M	$56M	$28M	$18M	$20M	$13M
Market Cap	$117M	$193M	$732M	$1.25B	$2.43B	$2.31B	$1.29B	$1.48B	$836M	$494M	$358M	·
P/E	-6.3	92.7	7.4	9.1	15.1	22.6	17.0	27.1	30.5	27.9	18.3	32.6
P/S	0.3	0.3	0.7	0.8	1.6	2.5	1.8	3.0	2.8	1.8	1.3	·
P/B	0.6	0.9	3.6	8.1	12.0	14.7	12.3	13.6	7.7	5.1	4.0	·
P / Tangible Book	0.6	0.9	3.6	8.1	12.0	14.7	·	·	·	·	·	·
P / Cash Flow	17.1	7.9	5.0	6.4	25.7	15.9	15.3	24.4	19.3	19.5	12.2	·
P / FCF	94.0	11.3	5.2	7.1	40.2	16.6	17.4	26.6	20.9	22.0	13.5	·
Dividend Yield	0.17%	0.37%	10.0%	5.7%	2.6%	2.3%	2.8%	1.6%	1.8%	2.4%	·	·
Earnings Yield	-15.9%	1.1%	13.5%	11.0%	6.6%	4.4%	5.9%	3.7%	3.3%	3.6%	5.5%	3.1%
Payout Ratio	-1.0%	34.2%	73.5%	49.9%	38.9%	51.7%	45.4%	41.5%	55.5%	66.7%	·	·
Annual Payout	$195.0K	$715.0K	$73M	$72M	$64M	$53M	$35M	$23M	$15M	$12M	·	·

Income Statement 15

Quarterly Income Statement data for MED
Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Revenue	$76M	$76M	$75M	$89M	$106M	$116M	$119M	$140M	$169M	$175M	$191M	$236M	$296M	$349M	$337M	$390M
Cost of Revenue	$23M	$24M	$23M	$27M	$29M	$31M	$31M	$34M	$45M	$47M	$50M	$58M	$85M	$103M	$104M	$108M
Gross Profit	$53M	$52M	$52M	$62M	$77M	$84M	$88M	$106M	$123M	$127M	$141M	$177M	$211M	$246M	$234M	$283M
SG&A Expense	$58M	$55M	$60M	$66M	$78M	$86M	$88M	$104M	$131M	$119M	$133M	$152M	$172M	$193M	$201M	$235M
Operating Income	$-4M	$-3M	$-8M	$-4M	$-1M	$-1M	$708.0K	$2M	$-8M	$8M	$9M	$26M	$39M	$54M	$33M	$48M
Interest Income	$1M	$1M	·	$1M	$1M	$1M	·	$1M	$1M	$1M	·	·	·	·	·	·
Other Non-op	$-11.0K	$-25.0K	$-1M	$-2.0K	$3M	$487.0K	$-2M	$-2M	$-4M	$4M	$-50.0K	$7.0K	$-51.0K	$-1.0K	$-710.0K	$-17.0K
Pretax Income	$-3M	$-2M	$-6M	$-3M	$3M	$526.0K	$1M	$2M	$-11M	$12M	$10M	$27M	$39M	$53M	$32M	$48M
Income Tax	$109.0K	$181.0K	$12M	$-396.0K	$395.0K	$1M	$474.0K	$449.0K	$-2M	$3M	$4M	$3M	$9M	$13M	$6M	$12M
Net Income	$-3M	$-2M	$-18M	$-2M	$2M	$-772.0K	$800.0K	$1M	$-8M	$8M	$6M	$23M	$30M	$40M	$27M	$36M
EPS (Basic)	$-0.28	$-0.19	$-1.65	$-0.21	$0.23	$-0.07	$0.08	$0.10	$-0.75	$0.76	$0.55	$2.12	$2.78	$3.68	$2.46	$3.30
EPS (Diluted)	$-0.28	$-0.19	$-1.64	$-0.21	$0.22	$-0.07	$0.08	$0.10	$-0.75	$0.76	$0.54	$2.12	$2.77	$3.67	$2.45	$3.27
Shares (Basic)	11,135,000	11,006,000	-21,949,000	10,991,000	10,991,000	10,948,000	-21,853,000	10,937,000	10,937,000	10,909,000	-21,760,000	10,892,000	10,888,000	10,864,000	-22,680,000	10,964,000
Shares (Diluted)	11,135,000	11,006,000	-22,018,000	10,991,000	11,060,000	10,948,000	-21,903,000	10,971,000	10,937,000	10,958,000	-21,828,000	10,933,000	10,917,000	10,899,000	-22,839,000	11,042,000
EBITDA	$-4M	$188.0K	·	$-4M	$-1M	$2M	·	$2M	$-8M	$11M	·	$26M	$39M	$56M	·	$48M

Balance Sheet 22

Quarterly Balance Sheet data for MED
Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Cash & Equivalents	$72M	$72M	$89M	$100M	$102M	$92M	$91M	$115M	$108M	$97M	·	$113M	$147M	$124M	·	$70M
Short-term Investments	$98M	$97M	$78M	$74M	$61M	$73M	$71M	$55M	$55M	$59M	·	·	·	·	·	$0
Inventory	$21M	$21M	$20M	$23M	$30M	$39M	$42M	$40M	$40M	$46M	·	$58M	$69M	$97M	·	$145M
Prepaid Expense	$6M	$7M	$9M	$7M	$9M	$10M	$10M	$7M	$12M	$11M	·	$8M	$13M	$10M	·	$14M
Current Assets	$202M	$203M	$202M	$208M	$206M	$214M	$214M	$225M	$224M	$220M	·	$224M	$229M	$230M	·	$230M
PP&E (Net)	$28M	$30M	$31M	$33M	$35M	$36M	$38M	$39M	$40M	$51M	·	$53M	$54M	$56M	·	$58M
PP&E (Gross)	·	·	$99M	·	·	·	$96M	·	·	·	·	·	·	·	·	·
Accum. Depreciation	·	·	$68M	·	·	·	$58M	·	·	·	·	·	·	·	·	·
Other Non-current Assets	$6M	$7M	$8M	$7M	$8M	$9M	$10M	$11M	$12M	$14M	·	$16M	$14M	$14M	·	$13M
Total Assets	$260M	$252M	$248M	$268M	$269M	$280M	$284M	$291M	$294M	$303M	·	$320M	$319M	$322M	·	$326M
Accounts Payable	$36M	$38M	$38M	$41M	$40M	$52M	$56M	$66M	$69M	$71M	·	$103M	$105M	$113M	·	$148M
Current Liabilities	$42M	$42M	$43M	$47M	$46M	$61M	$64M	$72M	$75M	$77M	·	$110M	$115M	$132M	·	$154M
Capital Leases	$22M	$12M	$6M	$7M	$7M	$8M	$10M	$12M	$13M	$15M	·	$17M	$18M	$19M	·	$22M
Total Liabilities	$64M	$54M	$49M	$54M	$53M	$69M	$74M	$84M	$88M	$92M	·	$127M	$133M	$151M	·	$176M
Common Stock	$11.0K	$11.0K	$11.0K	$11.0K	$11.0K	$11.0K	$11.0K	$11.0K	$11.0K	$11.0K	·	$11.0K	$11.0K	$11.0K	·	$11.0K
Paid-in Capital	$43M	$41M	$40M	$38M	$37M	$35M	$33M	$31M	$30M	$28M	·	$24M	$22M	$19M	·	$19M
Retained Earnings	$153M	$156M	$158M	$176M	$178M	$176M	$177M	$176M	$175M	$183M	·	$169M	$164M	$152M	·	$132M
Treasury Stock	·	·	·	·	·	·	·	·	·	·	·	$0	$0	$0	·	·
AOCI	$11.0K	$33.0K	$234.0K	$220.0K	$179.0K	$239.0K	$180.0K	$349.0K	$26.0K	$22.0K	·	$141.0K	$123.0K	$33.0K	·	$391.0K
Stockholders' Equity	$196M	$198M	$199M	$215M	$216M	$211M	$210M	$207M	$205M	$211M	$201M	$193M	$186M	$171M	$155M	$151M
Liabilities + Equity	$260M	$252M	$248M	$268M	$269M	$280M	$284M	$291M	$294M	$303M	·	$320M	$319M	$322M	·	$326M
Shares Outstanding	11,181,000	11,119,000	10,991,000	10,991,000	10,991,000	10,991,000	10,938,000	10,937,000	10,937,000	10,937,000	·	10,892,000	10,889,000	10,887,000	·	10,928,000

Cash Flow 14

Quarterly Cash Flow data for MED
Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
D&A	$3M	$3M	$3M	$3M	$4M	$3M	$3M	$3M	$3M	$3M	$3M	$3M	$3M	$3M	$3M	$3M
Stock-based Comp	$2M	$2M	$2M	$910.0K	$3M	$2M	$2M	$606.0K	$2M	$2M	$2M	$3M	$3M	$606.0K	$3M	$3M
Deferred Tax	·	$0	$12M	$-648.0K	$-20.0K	$20.0K	$-8M	$106.0K	$-103.0K	$112.0K	$7M	$-6M	$0	$800.0K	$822.0K	$-2M
Other Non-cash	·	$-3M	·	·	·	$-1M	·	·	·	$-7M	·	·	·	$20M	·	·
Operating Cash Flow	$2M	$260.0K	$-5M	$12M	$-3M	$3M	$-5M	$9M	$13M	$7M	$11M	$30M	$43M	$64M	$52M	$55M
CapEx	$969.0K	$1M	$1M	$1M	$1M	$2M	$2M	$1M	$2M	$2M	$946.0K	$2M	$2M	$2M	$9M	$2M
Investing Cash Flow	$-1M	$-17M	$-5M	$-14M	$13M	$-2M	$-19M	$-2M	$-3M	$-3M	$-11M	$-46M	$-2M	$-2M	$-9M	$-2M
Stock Repurchased	·	·	·	·	·	·	$0	$0	$0	$0	$0	$0	$0	$4M	$6M	$20M
Net Stock Activity	·	·	·	·	·	·	·	·	·	$0	·	·	·	$-4M	·	·
Dividends Paid	$83.0K	$87.0K	$0	$0	$1.0K	$194.0K	$0	$1.0K	$4.0K	$710.0K	$18M	$18M	$18M	$19M	$18M	$18M
Financing Cash Flow	$-83.0K	$-901.0K	$1.0K	$0	$-2.0K	$-563.0K	$-1.0K	$-3.0K	$-20.0K	$-1M	$-18M	$-18M	$-18M	$-26M	$-24M	$-45M
Net Change in Cash	$381.0K	$-18M	$-10M	$-2M	$10M	$789.0K	$-24M	$7M	$11M	$3M	$-18M	$-35M	$24M	$36M	$18M	$9M
Taxes Paid	·	$241.0K	·	·	·	$3M	·	·	·	$-100.0K	·	·	·	$-46.0K	$3M	$4M
Free Cash Flow	·	$-836.0K	·	·	·	$2M	·	·	·	$5M	·	·	·	$62M	·	·

Profitability 8

Quarterly Profitability data for MED
Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Gross Margin	69.9%	68.1%	·	69.5%	72.6%	72.8%	·	75.4%	73.2%	72.9%	·	75.2%	71.1%	70.6%	·	72.5%
Operating Margin	-5.7%	-4.3%	·	-4.6%	-1.0%	-1.1%	·	1.5%	-4.7%	4.5%	·	10.8%	13.1%	15.3%	·	12.3%
Net Margin	-4.1%	-2.8%	·	-2.5%	2.4%	-0.67%	·	0.81%	-4.8%	4.8%	·	9.8%	10.2%	11.5%	·	9.3%
Pretax Margin	-3.9%	-2.5%	·	-3.0%	2.7%	0.45%	·	1.1%	-6.3%	6.6%	·	11.3%	13.2%	15.3%	·	12.3%
EBITDA Margin	-5.7%	0.25%	·	-4.6%	-1.0%	1.7%	·	1.5%	-4.7%	6.4%	·	10.8%	13.1%	16.2%	·	12.3%
ROA	-1.2%	-0.80%	·	-0.81%	0.88%	-0.26%	·	0.37%	-2.7%	2.7%	·	7.2%	9.2%	10.8%	·	10.4%
ROE	-1.5%	-1.0%	·	-1.1%	1.2%	-0.37%	·	0.56%	-4.2%	4.4%	·	13.5%	19.2%	20.7%	·	20.8%
ROIC	-2.3%	-1.8%	·	-1.6%	-0.43%	0.88%	·	0.73%	-2.9%	2.7%	·	11.5%	16.2%	23.5%	·	24.2%

Liquidity & Solvency 2

Quarterly Liquidity & Solvency data for MED
Metric	Trend	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Current Ratio		4.9	4.8	·	4.4	4.5	3.5	·	3.1	3.0	2.8	·	2.0	2.0	1.7	·	1.5
Quick Ratio		4.1	4.0	·	3.7	3.5	2.7	·	2.3	2.2	2.0	·	1.0	1.3	0.9	·	0.5

Efficiency 2

Quarterly Efficiency data for MED
Metric	Trend	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Asset Turnover		0.3	0.3	·	0.3	0.4	0.4	·	0.5	0.6	0.6	·	0.7	0.9	0.9	·	1.1
Inventory Turnover		0.9	0.8	·	0.9	0.8	0.7	·	0.7	0.8	0.7	·	0.6	0.8	0.7	·	0.8

Per Share 6

Quarterly Per Share data for MED
Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Book Value / Share	$17.56	$17.78	·	$19.53	$19.65	$19.19	·	$18.96	$18.77	$19.29	·	$17.72	$17.04	$15.70	·	$13.77
Revenue / Share	$6.86	$6.91	·	$8.13	$9.54	$10.57	·	$12.78	$15.41	$15.95	·	$21.57	$27.13	$32.02	·	$35.36
Cash Flow / Share	·	$0.02	·	·	·	$0.31	·	·	·	$0.66	·	·	·	$5.88	·	·
Cash / Share	$6.43	$6.43	·	$9.06	$9.25	$8.34	·	$10.54	$9.88	$8.91	·	$10.35	$13.54	$11.37	·	$6.38
Dividend / Share	·	·	·	·	·	·	$0	$0	$0	$0	$0	$2	$2	$2	$2	$2
EPS (TTM)	$-0.46	$-0.25	·	$0.04	$-0.50	$0.04	·	$2.23	$4.90	$9.32	·	$11.83	$13.13	$13.95	·	$13.84

Valuation (TTM) 11

Quarterly Valuation (TTM) data for MED
Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Revenue TTM	$347M	$387M	·	$451M	$530M	$599M	·	$719M	$875M	$1.06B	·	$1.27B	$1.49B	$1.61B	·	$1.67B
Net Income TTM	$-5M	$-3M	·	$576.0K	$-5M	$519.0K	·	$24M	$54M	$102M	·	$130M	$146M	$157M	·	$159M
Market Cap	$119M	$113M	·	$150M	$154M	$148M	·	$209M	$239M	$419M	·	$815M	$1.00B	$1.13B	·	$1.18B
P/E	-23.1	-40.8	·	341.8	-28.1	337.0	·	8.6	4.5	4.1	·	6.3	7.0	7.4	·	7.8
P/S	0.3	0.3	·	0.3	0.3	0.2	·	0.3	0.3	0.4	·	0.6	0.7	0.7	·	0.7
P/B	0.6	0.6	·	0.7	0.7	0.7	·	1.0	1.2	2.0	·	4.2	5.4	6.6	·	7.9
P / Tangible Book	0.6	0.6	·	0.7	0.7	0.7	·	1.0	1.2	2.0	·	4.2	5.4	6.6	·	7.9
P / Cash Flow	·	435.8	·	·	·	43.5	·	·	·	57.6	·	·	·	17.6	·	·
P / FCF	·	-135.5	·	·	·	78.6	·	·	·	77.0	·	·	·	18.2	·	·
Earnings Yield	-4.3%	-2.5%	·	0.29%	-3.6%	0.30%	·	11.7%	22.5%	24.3%	·	15.8%	14.2%	13.5%	·	12.8%
Payout Ratio	·	-4.1%	·	·	·	-25.1%	·	·	·	8.5%	·	·	·	47.9%	·	·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue	$386M	$602M	$1.07B	$1.60B	$1.53B
Gross Margin %	71.3%	73.8%	72.4%	71.3%	73.9%
Operating Margin %	-3.7%	0.48%	11.8%	11.6%	14.2%
Net Income	$-19M	$2M	$99M	$144M	$164M
Diluted EPS	$-1.70	$0.19	$9.10	$12.73	$13.89

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Current Ratio	4.7	3.3	2.4	1.6	1.8
Quick Ratio	3.9	2.5	1.0	0.6	0.6

Cash Flow

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Free Cash Flow	$1M	$17M	$141M	$178M	$60M

My Metrics Your personal watchlist — selected rows from Full Fundamentals

📊

Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Institutional owners (13F) 125 filers · $86.3M total · As of June 30, 2026

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Institutional activity — Q2 2026 vs prior quarter

New positions	Exited positions	Increased	Decreased	Net shares change
31 (+4 vs prior Q)	24 (+7 vs prior Q)	47 (+10 vs prior Q)	26 (0 vs prior Q)	+421K

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution	Value	Shares	% of tracked 13F	Type
RENAISSANCE TECHNOLOGIES LLC	$8,261,052	778,610	9.57%	Shares
Steamboat Capital Partners, LLC	$7,498,076	706,699	8.69%	Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$5,758,047	542,700	6.67%	Call option
TWO SIGMA INVESTMENTS, LP	$5,107,452	481,381	5.92%	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$4,738,575	446,614	5.49%	Shares
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	$4,212,128	396,996	4.88%	Shares
DIMENSIONAL FUND ADVISORS LP	$3,748,163	353,267	4.34%	Shares
AMERICAN CENTURY COMPANIES INC	$3,383,646	318,911	3.92%	Shares
CITADEL ADVISORS LLC	$2,476,374	233,400	2.87%	Call option
AQR CAPITAL MANAGEMENT LLC	$2,434,846	229,486	2.82%	Shares
Peapod Lane Capital LLC	$2,361,531	222,576	2.74%	Shares
Lido Advisors, LLC	$2,337,779	220,337	2.71%	Shares
Trexquant Investment LP	$2,256,577	212,684	2.61%	Shares
GOLDMAN SACHS GROUP INC	$1,915,975	180,582	2.22%	Shares
COMMONS CAPITAL, LLC	$1,590,609	149,916	1.84%	Shares
Quinn Opportunity Partners LLC	$1,348,658	127,112	1.56%	Shares
BRIDGEWAY CAPITAL MANAGEMENT, LLC	$1,242,198	117,078	1.44%	Shares
RBF Capital, LLC	$1,156,490	109,000	1.34%	Shares
Walleye Trading LLC	$1,145,880	108,000	1.33%	Call option
TWO SIGMA ADVISERS, LP	$1,098,972	102,900	1.27%	Shares
MORGAN STANLEY	$1,082,586	102,034	1.25%	Shares
JANE STREET GROUP, LLC	$1,050,040	98,967	1.22%	Shares
GEODE CAPITAL MANAGEMENT, LLC	$1,037,962	97,758	1.20%	Shares
JPMORGAN CHASE & CO	$988,562	92,389	1.15%	Shares
Quantinno Capital Management LP	$880,598	82,997	1.02%	Shares
Divisadero Street Capital Management, LP	$847,092	79,839	0.98%	Shares
Virtus Family Office LLC	$838,827	79,060	0.97%	Shares
TUDOR INVESTMENT CORP ET AL	$806,689	76,031	0.93%	Shares
BNP PARIBAS FINANCIAL MARKETS	$783,846	73,878	0.91%	Shares
VANGUARD GROUP INC	$716,276	67,067	0.83%	Shares
BANK OF AMERICA CORP /DE/	$711,295	67,040	0.82%	Shares
CITADEL ADVISORS LLC	$696,016	65,600	0.81%	Put option
VANGUARD FIDUCIARY TRUST CO	$672,006	63,337	0.78%	Shares
Atom Investors LP	$659,083	62,119	0.76%	Shares
CITADEL ADVISORS LLC	$565,555	53,304	0.66%	Shares
STATE STREET CORP	$555,105	52,319	0.64%	Shares
Engineers Gate Manager LP	$528,686	49,829	0.61%	Shares
MILLENNIUM MANAGEMENT LLC	$508,283	47,906	0.59%	Shares
SummerHaven Investment Management, LLC	$507,529	47,835	0.59%	Shares
Centiva Capital, LP	$471,424	44,432	0.55%	Shares
Susquehanna Portfolio Strategies, LLC	$443,254	41,777	0.51%	Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$422,278	39,800	0.49%	Put option
VICTORY CAPITAL MANAGEMENT INC	$378,300	35,655	0.44%	Shares
Jain Global LLC	$373,716	35,223	0.43%	Shares
D. E. Shaw & Co., Inc.	$359,424	33,876	0.42%	Shares
PDT Partners, LLC	$347,541	32,756	0.40%	Shares
PEAK6 LLC	$333,154	31,400	0.39%	Call option
XTX Topco Ltd	$325,239	30,654	0.38%	Shares
FEDERATED HERMES, INC.	$321,578	30,309	0.37%	Shares
Marquette Asset Management, LLC	$318,704	30,038	0.37%	Shares
VANGUARD PORTFOLIO MANAGEMENT LLC	$308,836	29,108	0.36%	Shares
NORTHERN TRUST CORP	$265,749	25,047	0.31%	Shares
Chico Wealth RIA	$222,810	21,000	0.26%	Shares
Point72 Asset Management, L.P.	$222,799	20,999	0.26%	Shares
Squarepoint Ops LLC	$213,685	20,140	0.25%	Shares
State of Wyoming	$197,282	18,594	0.23%	Shares
Walleye Capital LLC	$182,492	17,200	0.21%	Call option
Empowered Funds, LLC	$182,418	17,193	0.21%	Shares
MERCER GLOBAL ADVISORS INC /ADV	$178,057	16,782	0.21%	Shares
Brevan Howard Capital Management LP	$159,415	15,025	0.18%	Shares
LITTLEJOHN FINANCIAL SERVICES, INC.	$146,779	13,834	0.17%	Shares
Advisors Asset Management, Inc.	$146,334	8,305	0.17%	Shares
Schonfeld Strategic Advisors LLC	$131,212	12,367	0.15%	Shares
WEALTH ENHANCEMENT ADVISORY SERVICES, LLC	$114,522	10,683	0.13%	Shares
IEQ CAPITAL, LLC	$113,951	10,740	0.13%	Shares
Verdad Advisers, LP	$108,583	10,234	0.13%	Shares
CWM, LLC	$92,056	9,034	0.11%	Shares
BlackRock, Inc.	$84,678	7,981	0.10%	Shares
Arax Advisory Partners	$79,257	7,470	0.09%	Shares
RHUMBLINE ADVISERS	$68,804	6,485	0.08%	Shares
Tower Research Capital LLC (TRC)	$63,618	5,996	0.07%	Shares
MARSHALL WACE, LLP	$58,025	5,469	0.07%	Shares
Russell Investments Group, Ltd.	$49,782	4,692	0.06%	Shares
Vanguard Global Advisers, LLC	$41,612	3,922	0.05%	Shares
Walleye Trading LLC	$36,074	3,400	0.04%	Shares
AlphaQuest LLC	$22,086	2,068	0.03%	Shares
FMR LLC	$21,995	2,073	0.03%	Shares
WELLS FARGO & COMPANY/MN	$20,859	1,966	0.02%	Shares
Walleye Capital LLC	$16,976	1,600	0.02%	Put option
Walleye Capital LLC	$15,406	1,452	0.02%	Shares
PNC Financial Services Group, Inc.	$13,432	1,266	0.02%	Shares
Integrated Wealth Concepts LLC	$11,289	1,064	0.01%	Shares
GAMMA Investing LLC	$11,056	1,042	0.01%	Shares
CREATIVE FINANCIAL DESIGNS INC /ADV	$10,610	1,000	0.01%	Shares
BARCLAYS PLC	$8,753	825	0.01%	Shares
Jump Financial, LLC	$8,488	800	0.01%	Shares
SIGNATUREFD, LLC	$7,395	697	0.01%	Shares
Pinnacle Wealth Planning Services, Inc.	$6,695	631	0.01%	Shares
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	$6,124	601	0.01%	Shares
JONES FINANCIAL COMPANIES LLLP	$6,055	576	0.01%	Shares
Allworth Financial LP	$5,550	523	0.01%	Shares
C M BIDWELL & ASSOCIATES LTD	$5,273	497	0.01%	Shares
Nuveen Asset Management, LLC	$5,092	289	0.01%	Shares
IFP Advisors, Inc	$4,658	439	0.01%	Shares
UBS Group AG	$3,639	343	0.00%	Shares
GREAT LAKES ADVISORS, LLC	$3,427	323	0.00%	Shares
Versant Capital Management, Inc	$3,289	310	0.00%	Shares
GILL CAPITAL PARTNERS, LLC	$1,101	108	0.00%	Shares
MJT & Associates Financial Advisory Group, Inc.	$1,061	100	0.00%	Shares
True Wealth Design, LLC	$955	90	0.00%	Shares

Company insiders 49 insiders · 21 officers · 26 directors

Insider	Role	Last activity	Shares owned	Net 12m
Daniel R Chard	Chairman & CEO	May 5, 2022 P	108,598	$0
Michael S Mcdevitt	Chief Executive Officer	Jan. 5, 2011 S	340,012	$0
James P. Maloney	Chief Financial Officer	July 20, 2022 F	2,944	$0
Timothy G Robinson	Chief Financial Officer	Feb. 20, 2020 F	47,214	$0
Connors Brendan	Chief Financial Officer	Jan. 5, 2011 S	91,484	$0
Mehrnaz Mona Ameli	President, OPTAVIA	Nov. 17, 2017 F	10,809	$0
Margaret Macdonald Sheetz	President & COO	April 1, 2016 S	327,346	$0
Jonathan Barrett Mackenzie	VP, Finance & CAO	March 16, 2022 A	657	$0
Stephen Kyle Johnson	VP, Finance & CAO	March 17, 2021 A	665	$0
Joseph P Kelleman	Vice President of Finance	Feb. 20, 2019 A	2,355	$0
Jason L Groves	Executive VP & General Counsel	Feb. 17, 2015 A	21,697	$0
Jeanette M. Mills	Executive Vice President	Aug. 18, 2014 S	20,116	$0
Guy Sheetz	Executive Vice President	Feb. 5, 2014 A	410,430	$0
Dominick Vietri	Executive Vice President	Feb. 5, 2014 A	3,804	$0
Brian Lloyd	Executive Vice President	Feb. 5, 2014 A	1,865	$0
Donald Gould	Executive Vice President	Feb. 5, 2014 A	6,804	$0
Brian Kagen	Executive Vice President	Feb. 5, 2014 A	3,804	$0
Jeanne M Uphouse	Executive Vice President	Feb. 5, 2014 A	3,804	$0
Brazdley T Macdonald	Exec. Chairman of the Board	Jan. 5, 2011 S	579,521	$0
Leo Williams	Executive Vice President	Nov. 29, 2010 S	15,000	$0
Robert J Hallock	Corporate Vice President	Nov. 18, 2003 P	1,000	$0
Jeffrey J Brown	Director	Aug. 9, 2022 P	3,940	$0
Andrea B Thomas	Director	Aug. 8, 2022 A	3,014	$0
Ming Xian	Director	Aug. 8, 2022 A	—	$0
Michael A. Hoer	Director	Aug. 8, 2022 A	5,138	$0
Scott Schlackman	Director	Aug. 8, 2022 A	7,260	$0
Constance J. Hallquist	Director	Aug. 8, 2022 A	7,882	$0
Kevin G Byrnes	Director	Nov. 11, 2021 M	14,922	$0
Michael C Macdonald	Director	Oct. 1, 2020 S	266,179	$0
Carl E Sassano	Director	July 17, 2020 G	18,199	$0
Charles P Connolly	Director	March 9, 2018 M	41,374	$0
Welling Glenn W.	Director	Dec. 1, 2017 S	22,380	$0
Jorgene K. Hartwig	Director	March 13, 2017 M	9,808	$0
Barry B Bondroff	Director	June 11, 2015 S	14,533	$0
John P Mcdaniel	Director	June 4, 2015 S	18,289	$0
Jerry D Reece	Director	Feb. 17, 2015 A	8,792	$0
Harvey C Barnum JR	Director	Feb. 17, 2015 A	8,742	$0
Catherine T Maguire	Director	Feb. 17, 2015 A	15,074	$0
Donald F Reilly	Director	Feb. 17, 2015 A	0	$0
George Lavin	Director	July 31, 2013 D	24,785	$0
Joseph D Calderone	Director	March 24, 2009 A	21,700	$0
Carthy Dennis Mc	Director	March 24, 2009 A	17,075	$0
Michael J Mcdevitt	Director	Feb. 15, 2007 A	17,400	$0
VISIUM BALANCED MASTER FUND, LTD.	10% owner	May 31, 2016 S	0	$0
Shirley Macdonald	—	May 12, 2010 S	0	$0
Mary T Travis	—	Dec. 17, 2009 S	12,583	$0
Richard J Law	—	Aug. 13, 2009 S	62,081	$0
RNI-NV Limited Partnership	—	Aug. 8, 2005 S	1,088,830	$0
Scott Zion	—	July 28, 2004 P	185,000	$0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

Activists & 5%+ owners 7 positions

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer	Filed	Stake	Status	Purpose	Filing
Steamboat Capital Partners, LLC, Parsa Kiai	March 20, 2026	6.00%	Initial filing	—	SEC
Engaged Capital Flagship Master Fund, LP, Engaged Capital Co-Invest X, LP, Engaged Capital Co-Invest X-A, LP, Engaged Capital Opportunities Fund, LP, Engaged Capital Flagship Fund, LP, Engaged Capital Flagship Fund, Ltd., Engaged Capital, LLC, Engaged Capital Holdings, LLC, Glenn W. Welling ×5 filings	July 15, 2020	—	Initial filing	—	SEC
Engaged Capital Master Feeder II, LP, Engaged Capital Master Feeder I, LP, Engaged Capital I, LP, Engaged Capital I Offshore, Ltd., Engaged Capital II, LP, Engaged Capital II Offshore Ltd., Engaged Capital, LLC, Engaged Capital Holdings, LLC, Glenn W. Welling	June 3, 2016	—	Initial filing	—	SEC
ModusLink Securities Corp., ModusLink Global Solutions, Inc. ×6 filings	Jan. 19, 2016	—	Initial filing	—	SEC
Engaged Capital Master Feeder I, LP, Engaged Capital Master Feeder II, LP, Engaged Capital I, LP, Engaged Capital I Offshore, Ltd., Engaged Capital II, LP, Engaged Capital II Offshore Ltd., Engaged Capital, LLC, Engaged Capital Holdings, LLC, Glenn W. Welling ×4 filings	Sept. 1, 2015	—	Initial filing	—	SEC
Undisclosed reporting person, Undisclosed reporting person	Dec. 12, 2002	—	Initial filing	—	SEC
Undisclosed reporting person, Undisclosed reporting person	May 6, 2002	—	Initial filing	Passive investment	SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

ETF ownership Held by 34 ETFs

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund	Weight	Units	As of	Source
VRIG · Invesco Actively Managed Exchange-T…	0.27%	5,000,000	Aug. 8, 2026	Daily
FSCC · Federated Hermes ETF Trust	0.13%	28,502 NS	May 31, 2026	N-PORT
JPSE · J.P. Morgan Exchange-Traded Fund Tr…	0.09%	48,444 NS	April 30, 2026	N-PORT
FNDA · SCHWAB STRATEGIC TRUST	0.05%	377,616 NS	May 31, 2026	N-PORT
SMLF · iShares Trust	0.03%	121,862 SH	Aug. 8, 2026	Daily
IWC · iShares Trust	0.03%	36,501 SH	Aug. 8, 2026	Daily
SFGV · EA Series Trust	0.02%	17,218 NS	May 29, 2026	N-PORT
GSSC · Goldman Sachs ETF Trust	0.01%	9,249 NS	May 31, 2026	N-PORT
AVUV · AMERICAN CENTURY ETF TRUST	0.01%	232,366 NS	May 31, 2026	N-PORT
VSS · VANGUARD INTERNATIONAL EQUITY INDEX…	0.01%	16,856 SH	Aug. 8, 2026	Daily
DFSV · Dimensional ETF Trust	0.01%	61,752 NS	April 30, 2026	N-PORT
AVSC · AMERICAN CENTURY ETF TRUST	0.01%	16,693 NS	May 31, 2026	N-PORT
PRFZ · Invesco Exchange-Traded Fund Trust	0.01%	13,206 SH	Aug. 8, 2026	Daily
FNDB · SCHWAB STRATEGIC TRUST	0.00%	4,892 NS	May 31, 2026	N-PORT
RSSL · Global X Funds	0.00%	4,682 NS	April 30, 2026	N-PORT
ITWO · ProShares Trust	0.00%	508 NS	May 31, 2026	N-PORT
DFAS · Dimensional ETF Trust	0.00%	37,570 NS	April 30, 2026	N-PORT
SCHA · SCHWAB STRATEGIC TRUST	0.00%	50,935 NS	May 31, 2026	N-PORT
UWM · ProShares Trust	0.00%	397 NS	May 31, 2026	N-PORT
URTY · ProShares Trust	0.00%	404 NS	May 31, 2026	N-PORT
DCOR · Dimensional ETF Trust	0.00%	2,019 NS	April 30, 2026	N-PORT
MSSM · MORGAN STANLEY PATHWAY FUNDS	0.00%	384 NS	May 31, 2026	N-PORT
HDG · ProShares Trust	0.00%	10 NS	May 31, 2026	N-PORT
AVUS · AMERICAN CENTURY ETF TRUST	0.00%	4,578 NS	May 31, 2026	N-PORT
SCHB · SCHWAB STRATEGIC TRUST	0.00%	7,873 NS	May 31, 2026	N-PORT
DFUS · Dimensional ETF Trust	0.00%	2,079 NS	April 30, 2026	N-PORT
DFAC · Dimensional ETF Trust	0.00%	5,600 NS	April 30, 2026	N-PORT
VXF · VANGUARD INDEX FUNDS	0.00%	115,543 SH	Aug. 8, 2026	Daily
VTI · VANGUARD INDEX FUNDS	0.00%	318,980 SH	Aug. 8, 2026	Daily
VXUS · VANGUARD STAR FUNDS	0.00%	64,351 SH	Aug. 8, 2026	Daily
VGK · VANGUARD INTERNATIONAL EQUITY INDEX…	0.00%	9,806 SH	Aug. 8, 2026	Daily
VT · VANGUARD INTERNATIONAL EQUITY INDEX…	0.00%	3,076 SH	Aug. 8, 2026	Daily
VEA · VANGUARD TAX-MANAGED FUNDS	0.00%	42,929 SH	Aug. 8, 2026	Daily
VSGX · VANGUARD WORLD FUND	0.00%	1,003 SH	Aug. 8, 2026	Daily

About MEDIFAST INC Common Stock Company overview from Wikipedia

Subsidiaries

History

False advertising settlement

MED Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

MED Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

Moving averages & overlays

Volume

Oscillators

Momentum & trend

10-Year Performance Revenue, net income, margins and EPS trends

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Profitability Gross, operating and net margins; ROE, ROA, ROIC

Financial Health Debt, liquidity, solvency — balance sheet strength

Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR

Per Share Metrics EPS, book value per share, cash flow per share, dividend per share

Capital Efficiency Asset turnover, inventory turnover, receivables turnover

Dividends Yield, payout ratio, dividend history, 5Y CAGR

MED Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

12-Month Price Target

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

Peer comparison (GICS sub-industry) Key metrics vs sector peers

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

My Metrics Your personal watchlist — selected rows from Full Fundamentals

Institutional owners (13F) 125 filers · $86.3M total · As of June 30, 2026

Company insiders 49 insiders · 21 officers · 26 directors

Activists & 5%+ owners 7 positions

ETF ownership Held by 34 ETFs